Being founded in 2017 and a division of Fosun Pharma, Shanghai Fosun Kairos Biotechnology Co., Ltd. is a high-tech biopharmaceutical enterprise. Fosun Kairos, since its establishment, has committed to the R&D, industrialization and commercialization of cell therapies against tumors, with the mission of "Cure the Incurable, Enlighten the Life" and its vision to be a most valuable leading one in the field of cell and gene therapy.
Fosun Kairos has introduced Yescarta®, a CAR-T therapy for treating relapsed or refractory non-Hodgkin lymphoma, from U.S. Kite Pharma and localized its production in China. In June 2021, Fosun Kairos received approval to launch China's first CAR-T therapy, YIKAIDA (Axicabtagene Ciloleucel Injection, a local version of Yescarta®). In June 2023, YIKAIDA was approved for another indication, i.e., the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. The launch of YIKAIDA marked the inaugural year of CAR-T therapy in China and continues to drive high-quality progress in lymphoma treatment.
Fosun Kairos has established a cell-therapy R&D center and a technology platform covering over 2000 square meters in Zhangjiang, Shanghai. Assembling a team of skilled scientists with high academic qualification from both domestic and abroad, the Company is dedicated to the early-stage research and development as well as evidence-based clinical projects of CAR-T, through technology license-in, independent innovation and cooperative development, aiming to build a sustainable innovation pipeline in cell therapy.
Looking forward, Fosun Kairos will function as the core platform for Fosun Pharma's cell therapy technologies, concentrating on tumor immunotherapy with a goal to reach the global market. It aims to become a worldwide leader in cell therapy, offering more hope for cures to patients globally.
Company Details
- Employees
- 76
- Founded
- -
- Address
- No.777 Shengrong Road, 3f,office Building,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.fosunkairos.com/
- Keywords
- Cell Therapy, Immunotherapy, CAR-T.
- HQ
- Shanghai, Shanghai
Fosun Kairos | 复星凯瑞 Questions
Fosun Kairos | 复星凯瑞's website is https://www.fosunkairos.com/
Fosun Kairos | 复星凯瑞's LinkedIn profile is https://cn.linkedin.com/company/fosunkairos
Fosun Kairos | 复星凯瑞 has
76 employees.
View email and phone details for 76
employees at Fosun Kairos | 复星凯瑞.
Fosun Kairos | 复星凯瑞's industry is
Biotechnology Research
Fosun Kairos | 复星凯瑞's top competitors are
Fosun Pharma,
Carsgen Therapeutics,
Astrazeneca,
Beigene,
Jw Therapeutics 药明巨诺,
Novartis,
Overland Pharmaceuticals,
Iaso Biotherapeutics（驯鹿生物）,
Kite Pharma,
Hengrui Pharma.
Fosun Kairos | 复星凯瑞's categories are Biotechnology Research
Fosun Kairos | 复星凯瑞's founding year is 2017
